Inclusion Criteria:  Acute ischemic stroke; 18 to 80 years of age; There are clear signs of neurological deficit: 8≤NIHSS score≤24; Received alteplase thrombolysis therapy within 4.5 hours after onset; Patients signed written inform consent  Exclusion Criteria:  Patients need endovascular therapy or bridge therapy; Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage; Severe head trauma or stroke, intracranial tumor or large intracranial aneurysm within 3 months; Intracranial or intraspinal surgery within 3 months; Active visceral hemorrhage Major surgery within 2 weeks or arterial puncture within 1 week that is difficult to compress the hemostatic site; Unknown onset time; Rapid improvement of symptoms or mild symptoms before thrombolysis therapy; A platelet count below 100,000/mm3 indicates a propensity for acute bleeding; Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase; Patients with severe mental disorders and dementia; ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis; Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or previously known severe renal diseases; Patients with malignant tumors or severe systemic disease; allergic to edaravone , (+)-Borneol or related excipients; Pregnant or lactating women; Have major surgery within 4 weeks before enrollment; Participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present; The investigators consider the patients are not suitable for this trial.